The Lucerne-based cleantech startup Bluetector addresses the steadily growing water market with an extremely competitive and innovative technology that is capable of cleaning various types of highly polluted wastewaters. Thanks to the funds raised, Bluetector will commence production of its BlueBoxes for first clients, including TOI TOI & DIXI.

SamanTree Medical, a digital microscopy company developing advanced fresh-tissue microscopy scanners, announces that it has raised CHF 4.5 million from private investors in a Series A Financing round.

Miracor Medical Systems announced today that it has closed an extension to its Series B financing. The new investors BioMedInvest and aws Gründerfonds (“aws Founders Fund”) and the existing investors - Earlybird Venture Capital, Delta Partners and SHS – provided the additional investment of EUR 4.5 million for Miracor to expand clinical trials and commercialization with the PICSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System.

Swiss biotech Genkyotex has raised CHF20 million ($21 million) in a venture financing. The funding, led by NeoMed Management, will help advance its lead product GKT137831 through clinical phase 2 as well as advance other NOX inhibitors through development. While in this strong financial position, Genkyotex is considering an IPO later in 2015, if the markets remain open for biotech.

The start-up company cashcloud has completed a third financing round with new investors. In total, several million Swiss francs were raised to be used in the coming months to develop and distribute the mobile cashcloud eWallet.

Nexthink, the unique provider of End-user IT Analytics, today announced that it has secured $14.5 million in a Series D round of funding, led by Auriga Partners with participation from new investor and entrepreneur Gilles Queru and existing investors VI Partners and Mannai Corporation. Nexthink has raised $29 million to date and plans to use the new funding to scale internationally, while further investing in the development of End-user IT Analytics solutions for mobility and cloud.

Lugano based start-up Right Shoes has closed a financing round with the second fund of Club Italia Investimenti (Cii). The solution of Right Shoes enables users to buy online shoes with the right size.

Good news from PB&B: The biotech company developing biodegradable microspheres for natural anti-aging Aesthetics has closed a first seed financing round. In addition the company has been awarded with the Trophée de l'Innovation 2014 of the University Hospitals Geneva (HUG).

Die Zürcher Kantonalbank und die BKW AG beteiligen sich am High-Tech Start-up Ampard AG. Dieses entwickelt und vermarktet europaweit das Energie-Management-System AMPARD, mit dem die Gesamtkosten von Batteriespeichern signifikant gesenkt werden können und der Immobilienbesitzer selber am Markt für Regelenergie partizipieren kann.

Anergis, a company developing proprietary ultra-fast allergy vaccines, today announced the closing of a Series B financing round totaling CHF 14.5 million (€ 12.1 million, US$ 15 million). All Series A investors participated in the round together with new private European and U.S.-based investors.

Xeltis,a privately-held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has raised EURO 27 million (USD 34 million/CHF 32 million) in an oversubscribed Series B financing.

Chemspeed is pleased to announce a new partnership with a group of Swiss investors organized by Investnet, a Swiss investors’ community. The resources brought in by Investnet enable Chemspeed to further boost its rapid growth path of the past years.